150000001875 compounds Chemical class 0.000 claims description 27.-1 NO2 halogens Chemical class 0.000 claims description 33.239000007790 solid phase Substances 0.000 title abstract description 21.238000010647 peptide synthesis reaction Methods 0.000 title abstract description 22.
Assignors: MILLIPORE INVESTMENT HOLDINGS LIMITED Anticipated expiration legal-status Critical Status Expired - Fee Related legal-status Critical Current Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US36298089A priority Critical Application filed by EMD Millipore Corp filed Critical EMD Millipore Corp Priority to US07/766,895 priority patent/US5233044A/en Application granted granted Critical Publication of US5233044A publication Critical patent/US5233044A/en Assigned to PERSEPTIVE BIOSYSTEMS, INC. Original Assignee EMD Millipore Corp Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Fee Related Application number US07/766,895 Inventor Derek Hudson Current Assignee (The listed assignees may be inaccurate.
#Pclp no2 pdf#
Google Patents Active esters for solid phase peptide synthesisĭownload PDF Info Publication number US5233044A US5233044A US07/766,895 US76689591A US5233044A US 5233044 A US5233044 A US 5233044A US 76689591 A US76689591 A US 76689591A US 5233044 A US5233044 A US 5233044A Authority US United States Prior art keywords phenyl amino acid pyrazolin derivatives coupling Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US5233044A - Active esters for solid phase peptide synthesis US5233044A - Active esters for solid phase peptide synthesis
0 kommentar(er)
